Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn’s disease
Version of Record online: 25 DEC 2001
Alimentary Pharmacology & Therapeutics
Volume 12, Issue 5, pages 419–424, May 1998
How to Cite
D’haens, Verstraete, Cheyns, Aerden, Bouillon and Rutgeerts (1998), Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn’s disease. Alimentary Pharmacology & Therapeutics, 12: 419–424. doi: 10.1046/j.1365-2036.1998.00321.x
- Issue online: 25 DEC 2001
- Version of Record online: 25 DEC 2001
Glucocorticosteroids are used frequently for the treatment of relapses of Crohn’s disease.
To investigate the influence of the new topically active glucocorticosteroid budesonide in comparison with methylprednisolone on bone turnover in a randomized open trial.
Twenty-nine patients received either budesonide (controlled ileal release formulation) 9 mg for 10 weeks, or methylprednisolone 32 mg (equivalent to 40 mg prednisone) orally for 3 weeks with subsequent tapering.
Patients who completed the trial with methylprednisolone (n = 8) had suppression of serum osteocalcin (30.2 ± 2.6 to 20.4 ± 2.0 ng/mL, P < 0.01), whereas no changes in this parameter of bone synthesis were observed during budesonide treatment (n = 11) (34.8 ± 3.1 to 33.0 ± 3.5 ng/mL). Urinary pyridinolines and deoxypyridinolines, highly sensitive markers of bone degradation, did not change in either group.
Short-term methylprednisolone therapy impairs osteoblast activity in patients with Crohn’s disease whereas budesonide does not.